Glycosylated hemoglobin Hb1Ac, a biomarker of diabetic peripheral neuropathy DPN
DOI:
https://doi.org/10.48047/HOM.10.2.2024.1744-1754Keywords:
Diabetic peripheral neuropathy, glycemic control HbA1c, Type 2 diabetes mellitusAbstract
Diabetic peripheral neuropathy (DPN) is strongly correlated with morbidity and death. DPN raises the possibility of non-traumatic amputation by facilitating foot ulcers and gangrene. Evidence suggests that only modest glycemic management, as measured by hemoglobin (HbA1c) levels, can prevent neuropathy. Weakened time-subordinate glucose control may be associated with microvascular complications in diabetes. Glycemic variability is also known to be a possible marker of poor glycemic control and a sign of diabetic complications.
Objective: The objective of this study is to investigate the relationship between Diabetic peripheral neuropathy (DPN) and glycosylated hemoglobin level Hb1Ac (<7.0%).
Method: An observational clinical study where a total of 62 diabetes mellitus (DM) type 2 patients with diabetic peripheral neuropathy DM/+DPN group( 32 females,39 Males, mean follow-up time 8 months, mean age 50±10 years, mean duration of diabetes diagnosis 12.1±9.5 years) and 10 type 1 diabetic patients without DPN (DM/-DPN group) were set as control. Blood samples were drawn from each patient and sent to the CPTH laboratory to analyze their glycemic profile.
Conclusion: In diabetics, there is a substantial correlation between elevated HbA1c levels and the development and progression of neuropathy. It is crucial to take into account additional variables, such as the length of diabetes, coexisting medical conditions, and patient differences in response to therapy.
Downloads
References
:Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. (2020). Type 2 Diabetes and its Impact on the Immune System. Current diabetes reviews, 16(5), 442–449. https://doi.org/10.2174/1573399815666191024085838
American Diabetes Association (2021). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes care, 44(Suppl 1), S15–S33. https://doi.org/10.2337/dc21-S002
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., Gabbay, R. A., … on behalf of the American Diabetes Association (2023). 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes care, 46(Suppl 1), S19–S40. https://doi.org/10.2337/dc23-S002
:Elafros, M. A., Andersen, H., Bennett, D. L., Savelieff, M. G., Viswanathan, V., Callaghan, B. C., & Feldman, E. L. (2022). Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. The Lancet. Neurology, 21(10), 922–936. https://doi.org/10.1016/S1474-4422(22)00188-0
:Nozawa, K., Ikeda, M., & Kikuchi, S. (2022). Association Between HbA1c Levels and Diabetic Peripheral Neuropathy: A Case-Control Study of Patients with Type 2 Diabetes Using Claims Data. Drugs – real world outcomes, 9(3), 403–414. https://doi.org/10.1007/s40801-022-00309-3
:Casadei, G., Filippini, M., & Brognara, L. (2021). Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy. Diseases (Basel, Switzerland), 9(1), 16. https://doi.org/10.3390/diseases9010016
: Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019). Diabetic neuropathy. Nature reviews. Disease primers, 5(1), 41. https://doi.org/10.1038/s41572-019-0092-1
:Li, J., Guan, R., & Pan, L. (2023). Mechanism of Schwann cells in diabetic peripheral neuropathy: A review. Medicine, 102(1), e32653. https://doi.org/10.1097/MD.0000000000032653
:Zhu, J., Hu, Z., Luo, Y., Liu, Y., Luo, W., Du, X., Luo, Z., Hu, J., & Peng, S. (2024). Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in endocrinology, 14, 1265372. https://doi.org/10.3389/fendo.2023.1265372
:Zhu, J., Hu, Z., Luo, Y., Liu, Y., Luo, W., Du, X., Luo, Z., Hu, J., & Peng, S. (2024). Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in endocrinology, 14, 1265372. https://doi.org/10.3389/fendo.2023.1265372
:Mizukami, H., & Osonoi, S. (2020). Pathogenesis and Molecular Treatment Strategies of Diabetic Neuropathy Collateral Glucose-Utilizing Pathways in Diabetic Polyneuropathy. International journal of molecular sciences, 22(1), 94. https://doi.org/10.3390/ijms22010094
:Wang, M., & Hng, T. M. (2021). HbA1c: More than just a number. Australian journal of general practice, 50(9), 628–632. https://doi.org/10.31128/AJGP-03-21-5866
:Song, J., Bai, H., Xu, H., Xing, Y., & Chen, S. (2022). HbA1c Variability and the Risk of Dementia in Patients with Diabetes: A Meta-Analysis. International journal of clinical practice, 2022, 7706330. https://doi.org/10.1155/2022/7706330
:Hunaifi, I., Agustriadi, I. G. N. O., Asmara, I. G. Y., & Budyono, C. (2021). The Correlation Between HbA1c and Neuropathy Disability Score in Type 2 Diabetes. Acta medica Indonesiana, 53(2), 164–168.
:Nathan, D. M., & DCCT/Edic Research Group. (2014). The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes care, 37(1), 9-16.
:Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, Chen T, Wang XQ. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018 Mar 29;17(1):47. Doi: 10.1186/s12933-018-0693-0. PMID: 29598819; PMCID: PMC5874999.
:Hossain, M. A., Sarkar, M. K., Mahbub, I., & Islam, S. M. (2021). A study on peripheral neuropathy and its related risk factors associated with hba1c levels. J Biosci (Rajshari), 29, 123-38.
:Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, Chen T, Wang XQ. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018 Mar 29;17(1):47. Doi: 10.1186/s12933-018-0693-0. PMID: 29598819; PMCID: PMC5874999.
:Xiong, X. F., Yang, Y., Wei, L., Xiao, Y., Li, L., & Sun, L. (2021). Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: A two‐step cluster analysis. Journal of Diabetes Investigation, 12(8), 1346-1358.
:Zhang, H., Chen, Y., Zhu, W., Niu, T., Song, B., Wang, H., Wang, W., & Zhang, H. (2023). The mediating role of HbA1c in the association between elevated low-density lipoprotein cholesterol levels and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Lipids in health and disease, 22(1), 102. https://doi.org/10.1186/s12944-023-01865-5
:Ishibashi, F., Taniguchi, M., Kosaka, A., Uetake, H., & Tavakoli, M. (2019). Improvement in neuropathy outcomes with normalizing HbA1c in patients with type 2 diabetes. Diabetes Care, 42(1), 110-118.
:Liu, X., Xu, Y., An, M., & Zeng, Q. (2019). The risk factors for diabetic peripheral neuropathy: A meta-analysis. PloS one, 14(2), e0212574. https://doi.org/10.1371/journal.pone.0212574
:Kaiafa, G., Veneti, S., Polychronopoulos, G., Pilalas, D., Daios, S., Kanellos, I., ... & Savopoulos, C. (2021). Is HbA1c an ideal biomarker of well-controlled diabetes? Postgraduate Medical Journal, 97(1148), 380-383.
:Francis, D., Kotteeswaran, K., & Veedu, P. P. (2024). Severity of Neuropathy-Related Disability and Associated Factors of Diabetic Peripheral Neuropathy in a Tertiary Healthcare Center: A Comparative Cross-Sectional Study. Cureus, 16(3).
:Ishibashi, F., Taniguchi, M., Kosaka, A., Uetake, H., & Tavakoli, M. (2019). Improvement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes. Diabetes care, 42(1), 110–118. https://doi.org/10.2337/dc18-1560
:Xu, F., Zhao, L. H., Su, J. B., Chen, T., Wang, X. Q., Chen, J. F., ... & Wang, X. H. (2014). The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetology & metabolic syndrome, 6, 1-7.
:Seo, Y. H., & Shin, H. Y. (2021). Relationship between hs-CRP and HbA1c in diabetes mellitus patients: 2015–2017 Korean National Health and Nutrition Examination Survey. Chonnam medical journal, 57(1), 62.
:Farooque, U., Lohano, A. K., Hussain Rind, S., Rind, M. S., Sr, Karimi, S., Jaan, A., Yasmin, F., & Cheema, O. (2020). Correlation of Hemoglobin A1c With Wagner Classification in Patients With Diabetic Foot. Cureus, 12(7), e9199. https://doi.org/10.7759/cureus.9199
:Critchley, J. A., Carey, I. M., Harris, T., DeWilde, S., Hosking, F. J., & Cook, D. G. (2018). Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study. Diabetes care, 41(10), 2127–2135. https://doi.org/10.2337/dc18-0287
:Lin, C. W., Hung, S. Y., Huang, C. H., Yeh, J. T., & Huang, Y. Y. (2019). Diabetic Foot Infection Presenting Systemic Inflammatory Response Syndrome: A Unique Disorder of Systemic Reaction from Infection of the Most Distal Body. Journal of Clinical Medicine, 8(10), 1538. https://doi.org/10.3390/jcm8101538
:Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019). Diabetic neuropathy. Nature reviews. Disease primers, 5(1), 41. https://doi.org/10.1038/s41572-019-0092-1
:Khdour, M. R. (2020). Treatment of diabetic peripheral neuropathy: a review. Journal of Pharmacy and Pharmacology, 72(7), 863-872.
:Yokoyama, H., Tsuji, T., Hayashi, S., Kabata, D., & Shintani, A. (2020). Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: A cross-sectional Japanese study (JDDM 52) using a non-linear model. Journal of diabetes investigation, 11(2), 450–457. https://doi.org/10.1111/jdi.13117
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Darakhshan waheed, Fazeelat Aziz, Shahbano Israr, Hafiz Jam Muhammad Mubashar, Hassnain Waqar, Habiba Nadeem Khan, Dr. Farah Naz Tahir (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
